Clearpoint Neuro (CLPT) Investor Presentation summary

Business overview and platform

• Enables cell, gene, and device therapies with precise navigation for brain and spine procedures, offering both clinical products and drug development services.

• Built a complete drug delivery ecosystem over 15+ years, including navigation, predictive modeling, delivery devices, and clinical support.

• Portfolio addresses a $500M current market and a $10B potential market across 60+ partners and 20+ indications.

• Over 100 global centers activated, scaling for increased cell and gene therapy demand.

• Team of engineers, scientists, and clinical specialists dedicated to neurosurgery and drug delivery innovation.

Market opportunity and disease focus

• More than 30 million people in the U.S. suffer from severe neurological disorders, with annual costs nearing $800 billion.

• Focus on diseases such as Parkinson's, essential tremor, epilepsy, Huntington's, rare genetic disorders, dementia, tumors, OCD, depression, ALS, stroke, and neuropathic pain.

• Few patients currently receive direct surgical interventions, highlighting unmet needs.

Strategic goals and growth drivers

• Aims to address barriers to treatment by developing therapies that cure underlying diseases and enabling minimally invasive, predictable procedures.

• Committed to expanding neuro drug delivery leadership, evolving portfolio for faster procedures, and increasing global center capacity.

• Four-pillar growth strategy: biologics & drug delivery, neurosurgery navigation, laser therapy & access, and global scale.

• Plans to activate 150 centers, grow revenue faster than operating expenses, and achieve cashflow breakeven.